With a median follow up of 58 (0-159,2) months,
acute and late upper gastro-enteric , rectal and genito-urinary toxicities are
presented in Table 1. One cystectomy due to the previous prostate bed
irradiation irradiation (G4) was observed. Median PSA at the last follow-up was
0,730 (0,00-4350,00) ng/ml. A biochemical relapse was registered in 62.9% of
pts. Clinical relapses were registered in 28,6% of patients and were localized
in: bone (13.7%), LN (10.9%), bone and LN (0.6%), bone and lung (0.6%), lung
(1.7%), pleural and mediastinum (0.6%) and prostate bed (0.6%). Only 4 relapses
(2.3%) were registered in the field of salvage radiotherapy, and another one in
field and distant (0.6%). At the last follow-up 66 pts were dead (37.7%), but
only 18.3% because of disease progression. Median biochemical relapse free
survival (bRFS) was 33.8 months, clinical relapse free survival (CRFS) was
137.5 months, cancer specific survival (CSS) was 147.7 months, and overall
survival (OS) was 110.4 months. 5-year Kaplan Meier estimates were: bRFS 35.3%,
CRFS 75.1% (see Fig. 1), CSS 82%, OS 67.3%.
Table 1. Acute and late toxicities of ENRT+SIB
for PCa LN relapses
Grade/Toxicity
| Acute gastro-enteric
| Acute rectal
| Acute genito-urinary
| Late gastro-enteric
| Late rectal
| Late genito-urinary
|
| G1 | 26.3% | 12.6% | 14.3% | 2.3% | 0.6% | 10.9% |
| G2 | 8.6% | 4% | 3.4% | 0 | 2.9% | 6.3% |
| G3 | 0 | 0 | 2.3% | 0 | 1.1% | 6.9% |
| G4 | 0 | 0 | 0 | 0 | 0 | 0.6% |
Fig. 1. Clinical Relapse Free Survival
